Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 4/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029151 | 0.87 | CCR2 (0.36) | KDM1AMAOBDRD2CYP3A4HPGD | |
| SCHEMBL3738774 | 0.76 | ALDH1A1 (0.55) | KDM1AMAOBTSHRCPB1KMT2A | |
| SCHEMBL3738767 | 0.76 | ALDH1A1 (0.55) | KDM1AMAOBTSHRCPB1KMT2A | |
| SCHEMBL5227953 | 0.76 | ALDH1A1 (0.55) | KDM1AMAOBTSHRCPB1KMT2A | |
| SCHEMBL21576725 | 0.71 | NAAA (0.44) | CYP3A4HPGDCYP2C19RAB9A | |
| SCHEMBL21576719 | 0.71 | NAAA (0.44) | CYP3A4HPGDCYP2C19RAB9A | |
| SCHEMBL27667807 | 0.71 | ALDH1A1 (0.52) | KDM1AMAOBDRD2TSHRCPB1 | |
| SCHEMBL3733860 | 0.71 | ALDH1A1 (0.52) | KDM1AMAOBDRD2TSHRCPB1 | |
| SCHEMBL5027125 | 0.71 | ALDH1A1 (0.52) | KDM1AMAOBDRD2TSHRCPB1 | |
| SCHEMBL3733857 | 0.71 | ALDH1A1 (0.52) | KDM1AMAOBDRD2TSHRCPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | KDM1A 3865/4885MAOB 3546/4885DRD2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.